Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
10.11817/j.issn.1672-7347.2020.190116
- Author:
Qian DENG
1
;
Erhua WANG
2
;
Xinyu WU
2
;
Qian CHENG
2
;
Jing LIU
2
;
Xin LI
3
Author Information
1. Department of Hematology, Third Hospital of Xiangya, Central South University, Changsha 410013, China. 18229771947@163.com.
2. Department of Hematology, Third Hospital of Xiangya, Central South University, Changsha 410013, China.
3. Department of Hematology, Third Hospital of Xiangya, Central South University, Changsha 410013, China. lixiner1975@163.com.
- Publication Type:Case Reports
- Keywords:
BCR-ABL1 T315I mutation;
axitinib;
chronic myeloid leukemia;
dasatinib
- MeSH:
Adult;
Axitinib;
Dasatinib;
therapeutic use;
Drug Resistance, Neoplasm;
drug effects;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
genetics;
Male;
Mutation;
Protein Kinase Inhibitors;
therapeutic use
- From:
Journal of Central South University(Medical Sciences)
2020;45(7):874-880
- CountryChina
- Language:English
-
Abstract:
Chronic myeloid leukemia (CML) is one of the most common hematological malignancies and characterized by the formation of Philadelphia (Ph) chromosome. Recently, tyrosine kinase inhibitors (TKI) treatment greatly improved the prognosis of CML. However, the options may be limited when a patient develops traditional TKI resistance or gene mutation. Herein, we reported a case. A 38-year-old male CML patient developed a BCR-ABL1 gene mutation of T315I after 2.5 years of TKI treatment, including imatinib and dasatinib. We adjusted the treatment with the combined application of dasatinib and axitinib. BCR-ABL1 gene copies dropped down and achieved an early molecular response at 2 months later. Subsequently, he received hematopoietic stem cell transplantation. Axitinib and dasatinib were applied for another half year after the allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two years after the allo-HSCT, the BCR-ABL1 gene was still undetectable. It provided a successful example in treating CML patients carrying BCR-ABL1 T315I mutation via combination of axitinib with conditional TKI.
